Article
Overcoming drug resistance in pancreatic cancer.
Expert opinion on therapeutic targets - 1 Jul 2011
Long Jiang, Zhang Yuqing, Yu Xianjun, Yang Jingxuan, LeBrun Drake G, Chen Changyi, Yao Qizhi, Li Min
Abstract excerpt
INTRODUCTION: Pancreatic cancer has the worst survival rate of all cancers. The current standard care for metastatic pancreatic cancer is gemcitabine, however, the success of this treatment is poor and overall survival has not improved for decades. Drug resistance (both intrinsic and acquired) is thought to be a major reason for the limited benefit of most pancreatic cancer therapies. AREAS COVERED: Previous...
Topics
- Antineoplastic Agents
- Drug Resistance, Neoplasm
- Epithelial-Mesenchymal Transition
- Humans
- Mutation
- Pancreatic Neoplasms
- Signal Transduction